Comparative Effectiveness of Treatments for Bacterial Vaginosis: A Network Meta-Analysis

• Published in: Antibiotics (Basel) 2021-08, Vol.10 (8), p.978
• Main Authors: Muñoz-Barreno, Alison, Cabezas-Mera, Fausto, Tejera, Eduardo, Machado, António
• Format: Article
• Language: English
• Subjects: Antibiotics; bacterial vaginosis; Bias; Clindamycin; Clinical trials; combined therapies; Datasets; Dysbacteriosis; Heterogeneity; Meta-analysis; Microbiota; Nitroimidazole; Oral administration; Pregnancy; Probiotics; randomized controlled trials; Regression analysis; Therapy; Vagina; Vaginosis
• ISSN: 2079-6382; 2079-6382
• DOI: 10.3390/antibiotics10080978

Bacterial vaginosis (BV) is a common vaginal dysbiosis in women of reproductive age. However, the cure rate for BV varies considerably and many women experience a relapse after the initial treatment. The present meta-analysis aimed to evaluate the clinical cure rates (CCRs) in randomized controlled trials (RCTs) through different therapies and administration routes. This meta-analysis included a final set of 25 eligible studies with a total of 57 RCTs and compared the effectiveness of BV treatments among non-pregnant and pregnant women. The initial range of CCRs varied greatly from 46.75% to 96.20% and the final pooled CCR was 75.5% (CI: 69.4–80.8) using the random model. The heterogeneity indices were Q = 418.91, I2 = 94.27%, and τ = 0.7498 (p < 0.0001). No publication bias was observed according to Funnel plot symmetry and Egger’s linear regression test (p = 0.1097). To evaluate different variables, sub-group analysis, meta-regressions, and network meta-analysis were also realized. The highest P-scores in CCR were obtained by: (1) a combined therapy with local probiotic treatment and application of antibiotics by both administration route (oral clindamycin and local 5-nitroimidazole; P-score = 0.92); (2) a combined therapy with oral administration of 5-nitroimidazole and probiotic treatment (P-score = 0.82); (3) and a combined therapy with local administration of 5-nitroimidazole and oral probiotic treatment (P-score = 0.68). A clear-cut decision of the best BV treatment was not possible due to the heterogeneity of outcomes reported in the trials, indicating the necessity for a better characterization of RCTs. Finally, combined therapies suggested the reduction of the optimal concentration of antibiotics, and double phase treatments of antibiotics indicated an increment of CCRs in BV.